US 12,011,445 B2
Prevention of pancreatic cell degeneration
Andrew G. Reaume, Exton, PA (US); Michael S. Saporito, Exton, PA (US); and Alexander R. Ochman, Exton, PA (US)
Assigned to Melior Pharmaceuticals I, Inc., Exton, PA (US)
Filed by Melior Pharmaceuticals I, Inc., Exton, PA (US)
Filed on Aug. 21, 2019, as Appl. No. 16/546,595.
Application 16/546,595 is a continuation of application No. 13/700,191, abandoned, previously published as PCT/US2011/038278, filed on May 27, 2011.
Claims priority of provisional application 61/349,231, filed on May 28, 2010.
Prior Publication US 2020/0215067 A1, Jul. 9, 2020
Int. Cl. A61K 31/513 (2006.01); A61P 3/10 (2006.01)
CPC A61K 31/513 (2013.01) [A61P 3/10 (2018.01)] 13 Claims
OG exemplary drawing
 
1. A method of treating pancreatic beta cell degeneration by increasing insulin content and preserving islet structure in pancreatic islets in a human in need thereof comprising administering to the human in need thereof an effective amount of a composition comprising a compound of formula:

OG Complex Work Unit Chemistry
wherein:
R1 is an alkyl group;
X is a halogen;
n is an integer from 0 to 5; and
m is 0 or 1;
wherein m+n is less than or equal to 5, thereby treating pancreatic beta cell degeneration.